
December 8, 2023
Two pancreatic cancer clinical trials now recruiting at UNC Lineberger
We have recently been added as a study location for two phase I clinical trials currently recruiting patients with pancreatic ductal adenocarcinoma (PDAC).
December 8, 2023
We have recently been added as a study location for two phase I clinical trials currently recruiting patients with pancreatic ductal adenocarcinoma (PDAC).
November 16, 2023
November 16, 2023
Kirsten Bryant, PhD, shares what motivates her in the lab, how mentorship and advocacy have fueled her passion for pancreatic cancer research, and why she's encouraged by progress made in the past decade.
August 1, 2023
Jen Yeh, MD, has been appointed to the Pancreatic Cancer Action Network’s scientific and medical advisory board, which is comprised of leading scientists, clinicians and healthcare professionals across the United States.
March 27, 2023
The NCI has awarded has awarded Shelley Earp, MD, and Yuliya Pylayeva-Gupta, PhD, a research project grant to investigate approaches to overcome barriers to pancreatic cancer immunotherapies.
October 7, 2022
UNC named UNC Lineberger’s Yuliya Pylayeva-Gupta, PhD, one of four recipients of the Phillip and Ruth Hettleman Prize for Artistic and Scholarly Achievement.
October 3, 2022
The National Cancer Institute has awarded the UNC Lineberger Pancreatic Cancer Center of Excellence a five-year, $10.9 million Pancreatic Cancer Specialized Program of Research Excellence (SPORE) grant.
September 26, 2022
The NCI awarded $9.3 million in support of two five-year research projects from researchers in the UNC Lineberger Pancreatic Cancer Center of Excellence in partnership with other institutions.
September 20, 2022
The Lustgarten Foundation has awarded its inaugural Lustgarten Equity, Accessibility, and Diversity (LEAD) Project grant to Jen Jen Yeh, MD, in support of her PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study).
September 13, 2022
UNC Lineberger’s Yuliya Pylayeva-Gupta, PhD, was the corresponding author of a paper published in Cell Reports Medicine that examined how B cells might be reprogrammed to improve anti-tumor immune response in pancreatic cancer. The study was led by a former research associate, Rahul Mirlekar.